COVID-19的眼部表现
本文综述COVID-19相关眼部表现的文献,涵盖现有证据评价、推测机制、合并症与危险因素、从初次感染到诊断的时间及临床警示信号。现有文献以病例报告和病例系列为主,缺乏对照组和因果证据;作者提出免疫失调、高凝状态及继发感染三条机制,并强调远程医疗分诊中识别可能危及视力或生命的眼病的重要性。
要点
- COVID-19眼部表现包括结膜炎、巩膜炎、葡萄膜炎、内源性眼内炎、角膜移植排斥、视网膜动静脉阻塞、非动脉炎性缺血性视神经病变、青光眼及神经和眼眶后遗症。
- 作者提出三条推测机制:感染后免疫失调相关炎症性眼病、高凝状态致血栓事件、重症住院及免疫抑制者继发感染(含眼内炎和鼻眶脑毛霉病)。
- 面对COVID-19传染性需考虑远程医疗会诊时,应识别感染期间或感染后可能出现的眼部病变,以及时进行面对面眼科检查。
核心结论
- COVID-19可能与不同严重程度和持续时间的眼部疾病相关,现有证据以病例报告和病例系列为主,缺乏对照组和因果证据。
- 随着新的基于人群和实验室研究数据的出现,将有可能更好地评估COVID-19对眼部的真实影响。
- 世界卫生组织于2023年5月宣布COVID-19大流行不再构成「全球卫生紧急事件」,但病例数仍在上升,不同变异株再感染预计将导致累积疾病负担增长。
研究设计与样本
- 本文为文献综述,讨论COVID-19相关眼部表现的文献,包括现有证据评价、推测机制、相关合并症与危险因素、从初次感染到诊断的时间及临床警示信号。
- 现有文献主要为病例报告和病例系列,不可避免地缺乏对照组和支持因果关系的证据。
主要发现
- COVID-19眼部表现被推测由三种主要机制所致:对初次感染的免疫失调与炎症性眼病相关;COVID-19患者更倾向于高凝状态,导致促血栓事件;需要住院的重症COVID-19患者因使用糖皮质激素或糖尿病等合并症而免疫抑制,继发感染(包括眼内炎和鼻眶脑毛霉病)风险增加。
- 报告的与COVID-19相关的眼科疾病包括结膜炎、巩膜炎、葡萄膜炎、内源性眼内炎、角膜移植排斥、视网膜动脉和静脉阻塞、非动脉炎性缺血性视神经病变、青光眼以及神经和眼眶后遗症。
临床怎么用
- 鉴于COVID-19的传染性需要考虑远程医疗会诊,理解感染期间或感染后可能出现的眼部疾病范围,对于确保患者被适当分诊、及时进行面对面眼科检查以处理可能危及视力和生命的疾病至关重要。
局限性
- 现有文献主要为病例报告和病例系列,不可避免地缺乏对照组和支持因果关系的证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is an increasing body of knowledge regarding how COVID-19 may be associated with ocular disease of varying severity and duration. This article discusses the literature on the ocular manifestations associated with COVID-19, including appraisal of the current evidence, suggested mechanisms of action, associated comorbidities and risk factors, timing from initial infection to diagnosis and clinical red flags. The current literature primarily comprises case reports and case series which inevitably lack control groups and evidence to support causality. However, these early data have prompted the development of larger population-based and laboratory studies that are emerging. As new data become available, a better appraisal of the true effects of COVID-19 on the eye will be possible. While the COVID-19 pandemic was officially declared no longer a "global health emergency" by the World Health Organization (WHO) in May 2023, case numbers continue to rise. Reinfection with different variants is predicted to lead to a growing cumulative burden of disease, particularly as more chronic, multi-organ sequelae become apparent with potentially significant ocular implications. COVID-19 ocular manifestations are postulated to be due to three main mechanisms: firstly, there is a dysregulated immune response to the initial infection linked to inflammatory eye disease; secondly, patients with COVID-19 have a greater tendency towards a hypercoagulable state, leading to prothrombotic events; thirdly, patients with severe COVID-19 requiring hospitalisation and are immunosuppressed due to administered corticosteroids or comorbidities such as diabetes mellitus are at an increased risk of secondary infections, including endophthalmitis and rhino-orbital-mucormycosis. Reported ophthalmic associations with COVID-19, therefore, include a range of conditions such as conjunctivitis, scleritis, uveitis, endogenous endophthalmitis, corneal graft rejection, retinal artery and vein occlusion, non-arteritic ischaemic optic neuropathy, glaucoma, neurological and orbital sequelae. With the need to consider telemedicine consultation in view of COVID-19's infectivity, understanding the range of ocular conditions that may present during or following infection is essential to ensure patients are appropriately triaged, with prompt in-person ocular examination for management of potentially sight-threatening and life-threatening diseases.
引用
- Ng HW, Scott DAR, Danesh-Meyer HV, et al. Ocular manifestations of COVID-19. Prog Retin Eye Res. 2024. PMID: 38925508. doi:10.1016/j.preteyeres.2024.101285
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。